Richard Levy
Director/Board Member bei MADRIGAL PHARMACEUTICALS, INC.
Vermögen: 3 Mio $ am 31.03.2024
Profil
Richard S.
Levy is currently serving as a Non-Executive Director at Gliknik, Inc., an Independent Director at Kiniksa Pharmaceuticals Ltd., Madrigal Pharmaceuticals, Inc., Kodiak Sciences, Inc., and Protara Therapeutics, Inc. He has previously worked as an Independent Director at Aquinox Pharmaceuticals, Inc. and Constellation Pharmaceuticals, Inc. He has also served as a Vice President at Celgene Corp., Chief Drug Development & Medical Officer, EVP at Incyte Corp., and Vice President at DuPont Pharmaceuticals Co. He started his career as an Assistant Professor at David Geffen School of Medicine.
Dr. Levy has an undergraduate degree from Brown University and doctorate degrees from the University of Pennsylvania and Perelman School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.04.2024 | 10 298 ( 0,05% ) | 3 Mio $ | 31.03.2024 | |
| 03.11.2023 | 7 777 ( 0,02% ) | 153 440 $ | 31.03.2024 | |
| 07.06.2023 | 31 000 ( 0,27% ) | 124 310 $ | 31.03.2024 | |
KODIAK SCIENCES, INC.
0,00% | 30.06.2023 | 1 000 ( 0,00% ) | 5 260 $ | 31.03.2024 |
Aktive Positionen von Richard Levy
| Unternehmen | Position | Beginn |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Director/Board Member | 11.08.2016 |
| KODIAK SCIENCES INC. | Director/Board Member | 18.07.2018 |
| KINIKSA PHARMACEUTICALS, LTD. | Director/Board Member | 04.03.2019 |
| PROTARA THERAPEUTICS, INC. | Director/Board Member | 01.12.2019 |
Gliknik, Inc.
 Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Director/Board Member | 19.02.2014 |
Ehemalige bekannte Positionen von Richard Levy
| Unternehmen | Position | Ende |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Director/Board Member | 01.06.2021 |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Director/Board Member | 08.08.2019 |
| INCYTE CORPORATION | Chief Tech/Sci/R&D Officer | 30.04.2016 |
| CELGENE | Corporate Officer/Principal | 01.01.2003 |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Richard Levy
| Brown University | Undergraduate Degree |
| University of Pennsylvania | Doctorate Degree |
| Perelman School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| MADRIGAL PHARMACEUTICALS, INC. | Health Technology |
| KODIAK SCIENCES INC. | Health Technology |
| PROTARA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Gliknik, Inc.
Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Health Technology |
DuPont Pharmaceuticals Co.
 DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Sandoz Corp.
 Sandoz Corp. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Sandoz Corp. develops, produces, and markets medicines. | Health Technology |
ArTara Subsidiary, Inc.
 ArTara Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ArTara Subsidiary, Inc. engages in the research and development of specialty diseases therapeutics. Its programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology or gastrointestinal and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY. | Health Technology |
